Inclusion Criteria
Inclusion Criteria (Patients):
- CD confirmed by biopsy for > 3 months duration
- Active disease (Harvey-Bradshaw Index > 8
- Failed standard therapy with; stable doses of 5-ASA >2 weeks; thiopurines >3 months;
or is steroid dependent at a dose <20mg/d; (inability to taper off steroid for longer
than 1 week)
- Stable medication regimen for >2 weeks.
- Age > 18 years old
Exclusion Criteria (Patients):
- Diagnosis of indeterminate colitis, or proctitis alone
- Severe or fulminate colitis
- Women who are pregnant or nursing
- Patients who are unable to give informed consent
- Patients who are unable or unwilling to undergo colonoscopy with moderate sedation
(>ASA class II)
- Patients who have previously undergone FMT
- Patients who have a confirmed malignancy or cancer
- Patients who are immunocompromised
- Treatment within last 12 weeks with cyclosporine, tacrolimus, infliximab, adalimumab,
certolizumab, natalizumab, thalidomide
- Antibiotic use within 2-months of start date
- Participation in a clinical trial in the preceding 30 days or simultaneously during
this trial
- Probiotic use within 30 days of start date
- Rectal therapy within 14 days of start date
- Decompensated cirrhosis
- Congenital or acquired immunodeficiencies
- Other comorbidities including:
- Diabetes mellitus, cancer, systemic lupus, must be able to tolerate conscious
sedation with colonoscopy
- Chronic kidney disease as defined by a GFR <60mL/min/1.73m2 44
- History of rheumatic heart disease, endocarditis, or valvular disease due to risk of
bacteremia from colonoscopy
- Steroid dose >20mg/day